Tamoxifen usage correlates with increased risk of Parkinson’s disease in older women with breast cancer: a case–control study in Taiwan

Lin, Hsien-Feng; Liao, Kuan‐Fu; Chang, Chi-Ching; Lin, Cheng‐Li; Lai, Shih‐Wei

doi:10.1007/s00228-017-2341-0

Cited by 19 publications

(18 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors explained the neuroprotective effect of estrogen might be disrupted by tamoxifen therapy [3]. Latourelle et al's finding was partially compatible with Lin et al's study showing a duration-dependent effect of tamoxifen therapy on the risk of Parkinson's disease [2]. That is, the longer the tamoxifen use, the higher the risk of Parkinson's disease.…”

mentioning

confidence: 67%

“…One article written by Montastruc et al reported that no association could be detected between tamoxifen therapy and Parkinsonism [1]. On the contrary, Lin et al reported that tamoxifen therapy was associated with a 3.3-fold increased risk of Parkinson's disease among older women with breast cancer in Taiwan [2]. A cohort study by Latourelle et al reported that tamoxifen therapy was associated with a 5-fold increased rate of Parkinson's disease after 4 years of tamoxifen therapy [3].…”

mentioning

confidence: 99%

See 1 more Smart Citation

Tamoxifen administration and risk of Parkinson’s disease

Lai

2018

Eur J Clin Pharmacol

Self Cite

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 67%

mentioning

confidence: 99%

Tamoxifen administration and risk of Parkinson’s disease

Lai

2018

Eur J Clin Pharmacol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Notably, the use of estrogen receptor antagonists (i.e., tamoxifen) are associated with increased Parkinson's disease risk in women [136][137][138]. However, the role of estrogen receptor antagonists in Alzheimer's disease risk in women is less clear [139][140][141][142][143].…”

Section: Discussionmentioning

confidence: 99%

Neuroprotective and neurotoxic outcomes of androgens and estrogens in an oxidative stress environment

et al. 2020

View full text Add to dashboard Cite

Background: The role of sex hormones on cellular function is unclear. Studies show androgens and estrogens are protective in the CNS, whereas other studies found no effects or damaging effects. Furthermore, sex differences have been observed in multiple oxidative stress-associated CNS disorders, such as Alzheimer's disease, depression, and Parkinson's disease. The goal of this study is to examine the relationship between sex hormones (i.e., androgens and estrogens) and oxidative stress on cell viability. Methods: N27 and PC12 neuronal and C6 glial phenotypic cell lines were used. N27 cells are female rat derived, whereas PC12 cells and C6 cells are male rat derived. These cells express estrogen receptors and the membraneassociated androgen receptor variant, AR45, but not the full-length androgen receptor. N27, PC12, and C6 cells were exposed to sex hormones either before or after an oxidative stressor to examine neuroprotective and neurotoxic properties, respectively. Estrogen receptor and androgen receptor inhibitors were used to determine the mechanisms mediating hormone-oxidative stress interactions on cell viability. Since the presence of AR45 in the human brain tissue was unknown, we examined the postmortem brain tissue from men and women for AR45 protein expression. Results: Neither androgens nor estrogens were protective against subsequent oxidative stress insults in glial cells. However, these hormones exhibited neuroprotective properties in neuronal N27 and PC12 cells via the estrogen receptor. Interestingly, a window of opportunity exists for sex hormone neuroprotection, wherein temporary hormone deprivation blocked neuroprotection by sex hormones. However, if sex hormones are applied following an oxidative stressor, they exacerbated oxidative stress-induced cell loss in neuronal and glial cells.

show abstract

“…Comorbidities were included as follows: alcohol‐related disease, cancer, cardiovascular disease (including coronary artery disease, heart failure, cerebrovascular disease and peripheral atherosclerosis), chronic liver disease (including cirrhosis, hepatitis B infection, hepatitis C infection and other chronic hepatitis), chronic obstructive pulmonary disease and diabetes mellitus. All comorbidities studied were diagnosed based on ICD‐9 codes, which have been well examined in previous studies 21‐25 …”

Section: Methodsmentioning

confidence: 99%

Risk of herpes zoster among patients with predialysis chronic kidney disease in a cohort study in Taiwan

Lai

Kuo²,

Lin

et al. 2020

Int. J. Clin. Pract.

Self Cite

View full text Add to dashboard Cite

Background/Objective Patients on chronic dialysis are at risk of developing herpes zoster, but little systematic research focuses on the association between predialysis chronic kidney disease and herpes zoster. The objective of the study was to explore the association between predialysis chronic kidney disease and herpes zoster in Taiwan. Methods A nation‐based retrospective cohort study was performed using the 2005‐2012 database of the Taiwan National Health Insurance Program. There were 16 655 subjects aged 20‐84 years with newly diagnosed predialysis chronic kidney disease as the study group and 33 310 randomly selected subjects without chronic kidney disease as the comparison group. Both groups were matched with sex, age, comorbidities and the year of the index date. The incidence rates of herpes zoster in both groups were calculated. The multivariable Cox proportional hazards regression model was used to estimate the hazard ratio (HR) and 95% confidence interval (CI) for herpes zoster associated with predialysis chronic kidney disease. Results The overall incidence rate of herpes zoster was 1.4‐fold higher in the predialysis chronic kidney disease group than that in the non‐chronic kidney disease group (8.76 vs 6.27 per 1000 person‐years, 95% CI 1.27‐1.54; P < .001). After controlling for co‐variables, the adjusted HR of herpes zoster was 1.38 (95% CI 1.25‐1.53; P < .001) for subjects with predialysis chronic kidney disease compared with non‐chronic kidney disease subjects. The adjusted HR increased to 1.65 for subjects with predialysis chronic kidney disease and with any comorbidity (95% CI 1.42‐1.92; P < .001). Conclusions Patients with predialysis chronic kidney disease correlate with approximately 1.4‐fold increased hazard of developing herpes zoster.

show abstract

Tamoxifen usage correlates with increased risk of Parkinson’s disease in older women with breast cancer: a case–control study in Taiwan

Abstract: Tamoxifen usage was associated with a 3.32-fold increase in the likelihood of having Parkinson's disease among older women with breast cancer in Taiwan.

Cited by 19 publications

References 79 publications

Tamoxifen administration and risk of Parkinson’s disease

Tamoxifen administration and risk of Parkinson’s disease

Neuroprotective and neurotoxic outcomes of androgens and estrogens in an oxidative stress environment

Risk of herpes zoster among patients with predialysis chronic kidney disease in a cohort study in Taiwan

Contact Info

Product

Resources

About